Last reviewed · How we verify
NCT04339608
Max COVID19- Study
trial in COVID-19 in 10,000 participants. Status unknown.
30 May 2020
Quick facts
| Lead sponsor | Max Healthcare Insititute Limited |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 2 April 2020 |
| Primary completion | 30 May 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across India |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Max Healthcare Insititute Limited
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In view of the increasing cases of COVID-19 in India and the possibility of the exponential rise of the cases, this study has been designed to collect data of the healthcare workers of Max Hospital and the general population. Our objective is to identify individuals with flu-like symptoms in suspicion of COVID-19 and follow them weekly up to 8 weeks until the pandemic resolves. The data will be collected through an online questionnaire circulated via Emails or WhatsApp.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevalence of Flu-like Symptoms and COVID-19 in Healthcare Workers from India.
Jha S, Soni A, Siddiqui S, Batra N, et al · · 2020 · cited 19× · PMID 32602677
Verify or expand the search:
- PubMed search for NCT04339608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Max Healthcare Insititute Limited trials
Trials by the same sponsor.
- NCT07496333 — The Effect of Virtual Reality Distraction on Pain During Colonoscopy · NA · completed
- NCT06456216 — Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Popul · completed
- NCT04422379 — COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective · unknown
- NCT04469660 — Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India · unknown
- NCT04374487 — Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04339608 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Max Healthcare Insititute Limited
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing